. 2022 Aug 17;8(1):e12320. doi: 10.1002/trc2.12320

TABLE 2.

Association between having an amyloid PET as part of initial workup and clinical management parameters at follow‐up (n = 352)

Variable	Follow‐up time ^a		Tests ordered ^b		DX variability ^c
Variable	Coef (SE)	p	Coef (SE)	p	Coef (SE)	p
Intercept	6.91 (4.62)	0.13	−2.40 (1.74)	0.48	−2.27 (0.77)	0.003
Amyloid PET ordered^*	2.76 (0.85)	0.001	0.17 (0.33)	0.59	0.45 (0.14)	0.001
Age	0.05 (0.05)	0.33	−0.04 (0.02)	0.03	−0.01 (0.01)	0.32
MoCA	−0.06 (0.09)	0.48	0.04 (0.04)	0.26	0.02 (0.02)	0.17
Cognitive syndrome ^**	−0.74 (0.91)	0.41	0.19 (0.36)	0.60	−0.34 (0.16)	0.03
Clinical diagnosis ^***	1.76 (0.82)	0.03	−0.84 (0.32)	0.009	−0.44 (0.13)	0.001
Met AUC criteria^****	−1.01 (0.88)	0.25	0.81 (0.41)	0.048	0.04 (0.14)	0.80

Variable	ChEI prescriptions ^d		Social work referrals ^c		Research referrals ^c
Variable	Coef (SE)	p	Coef (SE)	p	Coef (SE)	p
Intercept	0.06 (0.10)	0.07	−6.87 (1.79)	<0.001	−5.88 (1.76)	0.001
Amyloid PET ordered^*	1.24 (0.36)	0.46	0.21 (0.31)	0.50	0.001 (0.32)	0.99
Age	1.05 (0.02)	0.005	0.04 (0.02)	0.05	0.006 (0.02)	0.77
MoCA	0.93 (0.03)	0.01	−0.03 (0.03)	0.33	0.03 (0.03)	0.41
Cognitive syndrome^**	2.20 (0.65)	0.008	0.86 (0.31)	0.005	0.17 (0.31)	0.59
Clinical diagnosis ^***	0.89 (0.24)	0.67	−0.05 (0.27)	0.86	0.91 (0.34)	0.007
Met AUC criteria^****	1.05 (0.30)	0.87	−0.07 (0.28)	0.78	0.17 (0.31)	0.59

Abbreviations: DX: diagnosis, ChEI: cholinesterase inhibitors, Coef: coefficient, SE: standard error, MoCA: Montreal Cognitive Assessment, AUC: Appropriate Use Criteria

^{^a}

linear regression.

^{^b}

negative binomial regression.

^{^c}

Poisson regression adjusted for difference in follow‐up time.

^{^d}

logistic regression.

^* Referent: Ordered versus not ordered, ^** Referent: Dementia versus mild cognitive impairment, ^*** Referent: Alzheimer's disease (AD) versus Non‐AD, ^****Referent: yes versus no